Immune profiling facility in oncology

  • Clinical research
Hôpital PELLEGRIN, Laboratoire d’Immunologie-Immunogénétique



The GRIC offers a highly specialized immunoassay service providing support for the development of clinical research  programs relying on biological evaluation of immune parameters in patients.  This facility, incorporated in the hospital  structure, aims to provide:

  • a dynamic exploration of the immune system in patients receiving immune-modulating  agents in the context of clinical research trials,
  • develop and validate biomarkers employed in patient selection
  • identify potential combinations of therapeutic agents,
  • measure T cell immunity against antigens and determine the type of T  cell responses by analysis of secreted cytokines, allowing the identification of the type of induced specific immunity and  assessment of specific proliferation, thus addressing the quality of elicited T cells,
  • monitor biodrugs with mAbs  quantification, ADAb detection, dose and dosage interval optimization,
  • PK/PD studies on mAbs and antibody combinations.
    Practically, this facility performs flow cytometry, ELISA, ELISPOT, in vitro functional cellular assay, mass spectrometry.


  • Immunomonitoring : Multiparameter and high throughput flow cytometry, Elisa (single, and multiplex), Elispot  for phenotypic and functional characterization   of live cells.
  • Drug monitoring: Mass Spectrometry (LC-MS/MS, MRM mode) –PK population  and PK/PD modelling.
  • Patient’s efficacy and Immunotoxicity follow-up in therapeutic trials: Biotherapies, Immune-therapies  (immunomodulating therapeutic agents such as inhibitors of immune check-points, monoclonal antibody agonists, cytokines, etc…)
  • Evaluation of the biological markers associated with therapeutic response

Infrastructure and equipment

  • Immunology Clinical Research Laboratory (GRIC) in Immunology and Immunogenetic hospital Laboratory
  • Laboratoire de pharmacocinétique et de pharmacie clinique- Groupe PK/PD INSERM U1034, Pr D, Breilh;
  • Plate-forme d’histopathologie expérimentale de l'US 005 – UMS 3427 "TMB-CORE", Pr P. Dubus


  1. Couzi L, Levaillant Y, Jamai A, Pitard V, Lassalle R, Martin K, Garrigue I, Hawchar O, Siberchicot F, Moore N, Moreau J-F, Dechanet-Merville J, and Merville P. CMV-induced gamma-delta T cells associate with reduced cancer risk after kidney transplantation. J Am Soc Nephrol. (2010) 21: 181- 188.
  2. Duffau P, Seneschal J, Nicco C, Richez C, Lazaro E, Douchet I, Bordes C, Viallard JF, Goulvestre C, Pellegrin JL, Weil B, Moreau JF, Batteux F, Blanco P. . Sci Transl Med. 2010 Sep 1;2(47):47ra63.
  3. Wittkop L, Bitard J, Lazaro E, Neau D, Bonnet F, Mercie P, Dupon M, Hessamfar M, Ventura M, Malvy D, Dabis F, Pellegrin JL, Moreau JF, Thiébaut R, Pellegrin I; Groupe d'Epidémiologie Clinique du SIDA en Aquitaine. Effect of cytomegalovirus-induced immune response, self-antigen-induced immune response, and microbial translocation on chronic immune activation in successfully treated HIV type 1-infected patients: the ANRS CO3 Aquitaine Cohort. J Infect Dis. 2013 Feb 15;207(4):622
  4. Bachelet T, Couzi, L, Pitard V, Sicard X, Rigothier C, Lepreux S, Moreau JF, Taupin JL, Merville P and Déchanet-Merville J. CMV-responsive gamma-delta T cells : a novel cell effector in the antibody- mediated kidney graft microcirculation lesions. (2014) J Am Soc Nephrol, 25:2471-82


  • Laboratoire de pharmacocinétique et de pharmacie clinique- Groupe PK/PD INSERM U1034 Pr D. Breilh
  • Plate-forme d’histopathologie expérimentale de l'US 005 – UMS 3427 "TMB-CORE", Pr P. Dubus
  • Plateforme génomique (Pr JM Schmitter)
  • INSERM U897 (Pr Tzourio)
  • Agence Nationale de Recherche sur le SIDA et les Hépatites (ANRS), INSERM Paris
  • Centre de référence des Déficits immunitaires héréditaires (CEREDIH), hopital-necker.PARIS
  • UMR/CNRS 5164 –CIRID, Université de Bordeaux
  • INSERM U885 Université de Bordeaux  (Director : Pr Marthan Roger)
  • Laboratory of Immunology, Hopital Cochin. Paris  (Director: Pr Frederic Batteux).
  • Baylor Institute for Immunology Research. Dallas. Texas. USA.